COVID – 19 LATEST UPDATES
SEQENS mobilizes its innovation to support the unprecedented research on the covid-19 and prepares its unique industrial network for anti-virus production, for…
Read moreThis year, the Pierre Potier 2020 prize was awarded to Protéus by Seqens, the group’s biotech subsidiary specialized in enzymatic biocatalysis,…
Read moreOn July 27th, during the Protein Engineering Congress USA, Protéus by Seqens gave a talk on « Biocatalysis from lab to industrial scale », right…
Read moreREPLAY OF THE WEBINAR About BIOCATALYSIS On May 6th, Proteus by Seqens co-organized, together with the French bioeconomy cluster IAR a webinar on…
Read moreengineering of enzymatic cascades from D-serine This special issue highlights innovative organic chemistry research from academic and industrial chemists across France and its…
Read moreEfficient and safe process design combining SEQENS technical capabilities: Brilacidin as a case study As already mentioned in our previous article (“Seqens…
Read moreFocusing on biocatalysis for asymmetric synthesis and precious metal catalysts replacement The covid-19 crisis triggered an unprecedented mobilization of pharmaceutical research. Mid-April, 440…
Read moreAXENS and the Croatian oil company INA announced on 09 March 2020 an agreement for the construction of a 55 kt/year second…
Read moreProtéus by Seqens launches SEQENZYM®, Enzyme Kits selected among an extensive library of Extremophile Strains for Fast Early Screening of Biocatalysts…
Read moreReducing micropollutants, such as endocrine disruptors, is one of key issues in environmental management. Their presence in the environment, is most often related…
Read morePharma’s Almanac Magazine Advances in our understanding of enzymatic transformations and the increased availability of enzymes engineered for use in fine chemical synthesis…
Read more